HeartBeat.bio AG
PrivateLast Round
VC Round
Nov 2, 2023
Total Funding Raised
$6M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
HeartBeat.bio AG is a biotechnology company that develops a high-throughput human organoid and AI-supported drug discovery platform for heart disease.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HeartBeat.bio AG Comparables
Compare HeartBeat.bio AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genome Biologics | 88% | |
| Medera | 84% | |
| Valo Health | 80% |
HeartBeat.bio AG Funding Rounds
Historical fundraising activity
HeartBeat.bio AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Vienna Business Agency | Grant |
| Austria Wirtschaftsservice | Grant, Seed, VC Round |
| FFG Austrian Research Promotion Agency | Grant |
| INiTS | Seed |
| Invest AG | VC Round |
| Invest AG | VC Round |
| red-stars.com data | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 5, 2.5x the trailing average.
- Jan 20, 2026
Monthly visitors grew 106% MoM, reaching 7.5K.
Recent news
Latest coverage and updates
- hiresSep 17, 2026
Heartbeat engages Stanko Skrtic as Chief Development Officer to support its internal therapeutic pipeline and strategic partnerships in Austria on Aug 24th '26.
- is_developingSep 9, 2026
Heartbeat and Cubase Bio are launching the FACTS-3D collaboration to develop technologies for cardiovascular drug discovery in Austria, combining human heart organoids with three-dimensional spatial transcriptomics and receiving approximately €1 million in Eurostars funding on Sep 9th '26.
- is_developingSep 8, 2026
Heartbeat combines its Cardioid technology with Cubase Bio’s 3D spatial transcriptomics platform to develop a scalable approach for analyzing myocardial fibrosis mechanisms in Austria and Sweden, with joint development supported by Eurostars funding in Sep '26.
- partners_withSep 8, 2026
On Sep 8th '26 in Austria and Sweden, Heartbeat and Cubase Bio AB announce a strategic research collaboration to advance 3D spatial profiling of human cardiac organoids for cardiovascular drug discovery.
- is_developingAug 12, 2026
Heartbeat develops a scalable 3D human cardiac organoid platform with Molecular Devices and Axxam validates it in Italy, the United States, and Austria on Aug 12th '26 for drug toxicity and safety assessment.
HeartBeat.bio AG Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about HeartBeat.bio AG's valuation, stock price, and market status.
Is HeartBeat.bio AG a public or private company?
HeartBeat.bio AG is a private company.
What is the current stock price of HeartBeat.bio AG?
HeartBeat.bio AG is a private company, so its shares have no public market price. Caplight tracks HeartBeat.bio AG's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HeartBeat.bio AG worth (valuation)?
Valuation information for HeartBeat.bio AG is not publicly available.
Can I buy HeartBeat.bio AG stock?
HeartBeat.bio AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HeartBeat.bio AG's last funding round?
HeartBeat.bio AG's most recent funding round was VC Round on November 2, 2023.
Who are the main investors in HeartBeat.bio AG?
Key investors in HeartBeat.bio AG include Austria Wirtschaftsservice, Invest AG, red-stars.com data, Tensor Ventures, i&i Prague.
Will HeartBeat.bio AG IPO soon?
No public IPO plans have been announced for HeartBeat.bio AG.
How can I track HeartBeat.bio AG secondary market activity?
Caplight tracks bids, offers, and trades in HeartBeat.bio AG's shares on secondary markets.